UP!

AMGN $248.35   View long term graphs

Amgen Inc.
Formerly called
Applied Molecular Genetics
(1980–1983)
Type
Public
Traded as NASDAQ: AMGN
NASDAQ-100 Component
S&P 100 Component
S&P 500 Component
SEHK: 4332
Industry Biotechnology
Founded 1980
Headquarters Thousand Oaks, California, U.S.
Key people
Robert A. Bradway
(Chairman, President, and CEO)
Products Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, Xgeva, and Sensipar/Mimpara.
Revenue Increase US$22.99 billion (2016)
Operating income
Increase US$9.79 billion (2016)
Net income
Increase US$7.72 billion (2016)
Total assets Increase US$77.63 billion (2016)
Total equity Increase US$29.88 billion (2016)
Number of employees
19,200 (December 2016)
Website www.amgen.com

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.

The company has made at least five major corporate acquisitions.

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Amgen
(Founded 1983 as Applied Molecular Genetics)

Synergen Inc
(Acq 1994)

Kinetix Pharmaceuticals Inc
(Acq 2000)

Immunex Corporation
(Acq 2002)

Tularik Inc (Acq 2004)

Abgenix Inc
(Acq 2006)

Avidia Inc
(Acq 2006)

Alantos Pharmaceuticals
(Acq 2007)

Ilypsa Inc
(Acq 2007)

Alantos Pharmaceuticals Holdings Inc
(Acq 2007)

BioVex Group Inc
(Acq 2011)

Laboratório Químico Farmacêutico Bergamo Ltda
(Acq 2011)

Micromet Inc
(Acq 2012)

Mustafa Nevzat İlaç
(Acq 2012)

KAI Pharmaceuticals
(Acq 2012)

deCODE genetics
(Acq 2012)

Onyx Pharmaceuticals
(Acq 2013)

NextCODE genetics
(Spun off 2013)

Dezima Pharma
(Acq 2015)

Catherex
(Acq 2015)

As of December, 2013, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):

As of December 2013, Amgen had 11 drugs in Phase III clinical trials.

In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.

In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.

In June 2015 Amgen presented Phase 2 clinical trial data for their anti-CGRP antibody AMG 334 for migraine.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-01-28 Future report Set alerts
Q3 2020 2020-10-22 Future report Set alerts
Q2 2020 2020-07-28 4.25 3.05
Q1 2020 2020-04-30 4.17 3.07
Q4 2019 2020-01-30 3.64 2.85
Q3 2019 2019-10-29 3.66 3.27
Q2 2019 2019-07-30 3.97 3.57
Q1 2019 2019-04-30 3.56 3.18
Q4 2018 2019-01-29 3.42 3.01
Q3 2018 2018-10-30 3.69 2.86

Ratings

2016-07-13 Reiterated Rating Bank of America Corp. Hold $182.00
2016-07-13 Reiterated Rating Jefferies Group Buy $187.00
2016-07-12 Reiterated Rating BMO Capital Markets Buy
2016-06-29 Initiated Coverage Sanford C. Bernstein Market Perform $161.00
2016-06-29 Reiterated Rating Goldman Sachs Buy
2016-06-29 Reiterated Rating Morgan Stanley Overweight
2016-06-29 Reiterated Rating Goldman Sachs Group Inc. Buy
2016-06-26 Reiterated Rating Leerink Swann Hold
2016-06-15 Reiterated Rating Goldman Sachs Buy $202.00
2016-06-09 Reiterated Rating Leerink Swann Market Perform $186.00
2016-06-09 Reiterated Rating BMO Capital Markets Outperform $186.00
2016-06-08 Reiterated Rating Bank of America Hold $182.00
2016-06-08 Reiterated Rating Bank of America Corp. Hold $182.00
2016-05-19 Reiterated Rating Bank of America Hold
2016-05-19 Reiterated Rating Morgan Stanley Buy
2016-05-18 Reiterated Rating RBC Capital Buy
2016-05-18 Reiterated Rating Royal Bank Of Canada Buy
2016-05-16 Reiterated Rating Robert W. Baird Hold
2016-05-10 Reiterated Rating Piper Jaffray Buy
2016-05-10 Reiterated Rating Piper Jaffray Cos. Buy
2016-05-01 Reiterated Rating Leerink Swann Market Perform $179.00 to $186.00
2016-04-30 Reiterated Rating Piper Jaffray Buy
2016-04-30 Reiterated Rating BMO Capital Markets Buy $183.00 to $186.00
2016-04-29 Reiterated Rating Morgan Stanley Buy $195.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-08 Boost Price Target Morgan Stanley $193.00 to $195.00
2016-04-05 Initiated Coverage BMO Capital Markets Outperform $183.00
2016-04-05 Reiterated Rating Leerink Swann Market Perform
2016-03-29 Reiterated Rating Morgan Stanley Overweight $193.00
2016-03-16 Reiterated Rating RBC Capital Buy $190.00
2016-03-16 Reiterated Rating Piper Jaffray Overweight $191.00
2016-03-08 Reiterated Rating Cowen and Company Outperform $193.00
2016-03-03 Reiterated Rating Piper Jaffray Buy $200.00 to $191.00
2016-02-25 Initiated Coverage Citigroup Inc. Neutral $165.00
2016-02-23 Reiterated Rating BTIG Research Sell $135.00
2016-02-22 Reiterated Rating Cowen and Company Outperform $193.00
2016-02-22 Reiterated Rating JPMorgan Chase & Co. Neutral $165.00
2016-02-22 Lower Price Target Goldman Sachs $218.00 to $201.00
2016-02-11 Reiterated Rating Jefferies Buy $187.00
2016-02-11 Reiterated Rating Jefferies Group Buy $187.00
2016-02-08 Lower Price Target Argus Buy $202.00 to $185.00
2016-02-06 Reiterated Rating Leerink Swann Hold
2016-02-04 Initiated Coverage Leerink Swann Market Perform $179.00
2016-01-29 Reiterated Rating Credit Suisse Buy
2016-01-29 Boost Price Target Morgan Stanley $189.00 to $193.00
2016-01-29 Lower Price Target JPMorgan Chase & Co. Neutral $174.00 to $165.00
2016-01-29 Boost Price Target Goldman Sachs $213.00 to $218.00
2016-01-29 Reiterated Rating Credit Suisse Group AG Buy
2016-01-28 Reiterated Rating Cowen and Company Buy
2016-01-28 Reiterated Rating Piper Jaffray Buy $200.00
2016-01-28 Reiterated Rating JPMorgan Chase & Co. Neutral $174.00 to $165.00
2016-01-22 Reiterated Rating Wells Fargo Hold
2016-01-22 Reiterated Rating Wells Fargo & Co. Hold
2016-01-19 Initiated Coverage Credit Suisse Outperform $205.00
2016-01-13 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-01-09 Reiterated Rating Jefferies Group Buy
2016-01-08 Reiterated Rating Piper Jaffray Buy $200.00
2016-01-07 Initiated Coverage BTIG Research Sell $135.00
2015-12-18 Initiated Coverage Atlantic Securities Overweight $202.00
2015-12-14 Upgrade Morgan Stanley Equal Weight to Overweight $160.00 to $193.00
2015-12-09 Reiterated Rating JPMorgan Chase & Co. Neutral $174.00
2015-12-04 Initiated Coverage Wells Fargo Market Perform
2015-11-05 Upgrade Piper Jaffray Overweight
2015-10-29 Reiterated Rating Piper Jaffray Overweight $200.00
2015-10-29 Boost Price Target Morgan Stanley $160.00
2015-10-29 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-10-12 Reiterated Rating Piper Jaffray Overweight $200.00
2015-09-22 Reiterated Rating Nomura Buy $190.00 to $191.00
2015-09-22 Reiterated Rating Nomura Holdings Inc. Buy $190.00 to $191.00
2015-09-02 Reiterated Rating Sanford C. Bernstein Hold
2015-08-31 Initiated Coverage Raymond James Market Perform
2015-08-31 Initiated Coverage Raymond James Financial Inc. Market Perform
2015-08-28 Reiterated Rating Piper Jaffray Buy $200.00
2015-08-28 Boost Price Target Jefferies Group Buy $195.00 to $197.00
2015-08-17 Reiterated Rating Deutsche Bank Buy $195.00
2015-08-17 Reiterated Rating Deutsche Bank AG Buy $195.00
2015-08-14 Reiterated Rating RBC Capital Outperform $190.00
2015-08-12 Reiterated Rating Cowen and Company Buy $193.00
2015-07-31 Reiterated Rating JPMorgan Chase & Co. Neutral $174.00
2015-07-31 Reiterated Rating Cowen and Company Outperform $189.00 to $193.00
2015-07-31 Boost Price Target Piper Jaffray Overweight $200.00
2015-07-31 Boost Price Target Barclays Equal Weight $180.00 to $185.00
2015-07-31 Reiterated Rating Deutsche Bank Buy $192.00 to $195.00
2015-07-31 Boost Price Target Barclays PLC Equal Weight $180.00 to $185.00
2015-07-29 Reiterated Rating RBC Capital Outperform $185.00 to $190.00
2015-07-23 Reiterated Rating Piper Jaffray Buy $192.00
2015-06-25 Reiterated Rating Deutsche Bank Buy $192.00
2015-06-12 Reiterated Rating Nomura Buy $182.00
2015-06-11 Reiterated Rating Jefferies Group Buy $195.00
2015-06-11 Reiterated Rating Deutsche Bank Buy $192.00
2015-06-07 Reiterated Rating Cowen and Company Outperform $189.00
2015-06-03 Reiterated Rating Piper Jaffray Overweight $192.00
2015-05-28 Lower Price Target Deutsche Bank Buy $200.00 to $192.00
2015-05-27 Reiterated Rating JPMorgan Chase & Co. Neutral $160.00
2015-05-26 Reiterated Rating Morgan Stanley Equal Weight $179.00 to $171.00
2015-05-26 Reiterated Rating JPMorgan Chase & Co. Neutral $160.00
2015-05-09 Reiterated Rating Goldman Sachs Buy
2015-05-08 Set Price Target Piper Jaffray Buy $192.00
2015-05-04 Reiterated Rating Bank of America Neutral
2015-04-30 Reiterated Rating Piper Jaffray Overweight $192.00
2015-04-23 Reiterated Rating Barclays Neutral to Equal Weight
2015-04-22 Lower Price Target Nomura Buy $194.00 to $191.00
2015-04-22 Boost Price Target Jefferies Group Buy $182.00 to $195.00
2015-04-22 Boost Price Target Leerink Swann Buy $187.00
2015-04-22 Boost Price Target RBC Capital Outperform $178.00 to $185.00
2015-04-16 Reiterated Rating Piper Jaffray Overweight $187.00
2015-03-23 Set Price Target Bank of America Hold $179.00
2015-03-19 Reiterated Rating Deutsche Bank Buy $195.00
2015-03-18 Reiterated Rating Piper Jaffray Overweight $187.00
2015-03-02 Reiterated Rating JPMorgan Chase & Co. Hold
2015-03-02 Reiterated Rating Piper Jaffray Overweight $187.00
2015-02-13 Set Price Target Piper Jaffray Buy $187.00
2015-01-28 Set Price Target Credit Suisse Hold $180.00
2015-01-06 Initiated Coverage Barclays Equal Weight $180.00
2015-01-06 Reiterated Rating JPMorgan Chase & Co. Neutral $163.00
2015-01-05 Boost Price Target Nomura $200.00
2015-01-05 Downgrade Morgan Stanley Overweight to Equal Weight $165.00 to $177.00
2014-12-17 Boost Price Target Deutsche Bank $195.00
2014-11-12 Reiterated Rating Deutsche Bank Positive to Buy $192.00 to $190.00
2014-10-29 Boost Price Target Argus Buy $140.00 to $185.00
2014-10-29 Reiterated Rating Citigroup Inc. Buy $162.00 to $185.00
2014-10-29 Reiterated Rating Credit Suisse Neutral $135.00 to $160.00
2014-10-29 Upgrade Nomura Neutral to Buy $144.00 to $193.00
2014-10-28 Reiterated Rating Jefferies Group Buy $142.00 to $172.00
2014-10-28 Reiterated Rating Nomura Neutral to Buy $193.00 to $144.00
2014-10-28 Reiterated Rating Deutsche Bank Buy $163.00 to $190.00
2014-10-28 Boost Price Target RBC Capital Outperform $150.00 to $165.00
2014-10-27 Boost Price Target Piper Jaffray Overweight $150.00 to $170.00
2014-10-01 Initiated Coverage Bank of America Neutral $152.00
2014-09-17 Boost Price Target Morgan Stanley Overweight $143.00 to $151.00
2014-09-08 Reiterated RBC Capital Mkts Outperform $138 to $150
2014-09-08 Boost Price Target RBC Capital Outperform $138.00 to $150.00
2014-09-02 Boost Price Target Leerink Swann Market Perform $140.00 to $153.00
2014-08-04 Reiterated Rating Argus Buy $135.00 to $140.00
2014-07-31 Boost Price Target Leerink Swann $135.00 to $140.00
2014-07-31 Boost Price Target Credit Suisse $125.00 to $135.00
2014-07-31 Boost Price Target Cowen and Company $131.00 to $145.00
2014-07-30 Reiterated RBC Capital Mkts Outperform $125 to $138
2014-07-30 Reiterated Rating Deutsche Bank Buy $149.00 to $160.00
2014-07-30 Reiterated Rating Nomura Neutral $129.00 to $142.00
2014-07-30 Reiterated Rating Citigroup Inc. Buy $155.00 to $159.00
2014-07-30 Boost Price Target BMO Capital Markets $125.00 to $135.00
2014-07-30 Boost Price Target RBC Capital Outperform $125.00 to $138.00
2014-07-18 Boost Price Target Deutsche Bank Buy $144.00 to $149.00
2014-06-10 Reiterated Rating Morgan Stanley Overweight $140.00
2014-05-12 Reiterated Rating Morgan Stanley Overweight $140.00
2014-05-12 Reiterated Rating Deutsche Bank Buy
2014-04-23 Boost Price Target Oppenheimer Market Perform $121.00 to $122.00
2014-04-23 Reiterated Rating Jefferies Group Buy $145.00 to $142.00
2014-04-23 Reiterated Rating Deutsche Bank Buy $142.00 to $144.00
2014-04-23 Boost Price Target Nomura Neutral $129.00
2014-03-28 Boost Price Target Jefferies Group Buy $138.00 to $145.00
2014-03-26 Initiated Coverage Morgan Stanley Overweight $140.00
2014-03-21 Boost Price Target Barclays Equal Weight $115.00 to $130.00
2014-03-18 Boost Price Target Citigroup Inc. Buy $155.00
2014-01-31 Boost Price Target Argus Buy $130.00 to $135.00
2014-01-29 Boost Price Target Jefferies Group $133.00 to $138.00
2014-01-27 Upgrade Ned Davis Research Neutral to Buy
2014-01-08 Initiated Coverage Nomura Neutral $131.00
2013-12-06 Reiterated Rating Citigroup Inc. Buy $139.00 to $131.00
2013-11-26 Initiated Coverage Piper Jaffray Overweight $143.00
2013-11-20 Reiterated Rating Deutsche Bank Buy $138.00 to $142.00
2013-11-18 Reiterated Rating Goldman Sachs Conviction-Buy $140.00
2013-11-07 Reiterated Rating Goldman Sachs Conviction-Buy $140.00
2013-10-23 Boost Price Target Brean Capital Buy $119.00 to $132.00
2013-10-22 Reiterated Rating Deutsche Bank Buy
2013-10-02 Reiterated Rating Leerink Swann Market Perform $128.00
2013-09-24 Boost Price Target BMO Capital Markets Market Perform $108.00 to $116.00
2013-08-29 Reiterated UBS Buy $121 to $124
2013-08-27 Reiterated Barclays Overweight $105 to $115
2013-07-31 Reiterated Oppenheimer Perform $100 to $109
2013-04-08 Reiterated RBC Capital Mkts Outperform $95 to $105
2013-01-25 Upgrade Argus Hold to Buy $96
2013-01-24 Reiterated UBS Buy $96 to $98
2012-09-12 Downgrade Robert W. Baird Outperform to Neutral $84
2012-09-10 Upgrade UBS Neutral to Buy $80 to $96
2012-08-02 Downgrade Argus Buy to Hold
2012-02-09 Downgrade Oppenheimer Outperform to Perform
2011-09-09 Downgrade Standpoint Research Buy to Hold
2011-05-10 Reiterated MP Advisors Outperform $63 to $65
2011-04-25 Reiterated Stifel Nicolaus Buy $70 to $68
2016-07-13 Reiterated Rating Bank of America Corp. Hold $182.00
2016-07-13 Reiterated Rating Jefferies Group Buy $187.00
2016-07-12 Reiterated Rating BMO Capital Markets Buy
2016-06-29 Initiated Coverage Sanford C. Bernstein Market Perform $161.00
2016-06-29 Reiterated Rating Goldman Sachs Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
AMGEN INC 0.07%  (541399) AMGN / TLOG /
Bradway Robert A Chairman, CEO and President 0.06%  (433413) AMGN / BA / NSC /
Amgen Ventures LLC 0.04%  (334126) AMGN /
HOOPER ANTHONY C EVP, Global Commercial Ops. 0.03%  (216030) AMGN /
OMENN GILBERT S 0.02%  (180547) AMGN / ESPR / GALT /
MCNAMEE BRIAN M EVP 0.01%  (102516) AMGN /
Peacock Jonathan M EVP & CFO 0.01%  (94414) AMGN / KITE /
SCOTT DAVID J SVP, Gen. Counsel & Secy. 0.01%  (93949) AMGN /
Harper Sean E EVP, Research & Development 0.01%  (61296) AMGN /
Meline David W EVP & CFO 0.01%  (60155) AMGN / MMM / TRW /
HERRINGER FRANK C 0.01%  (50875) AMGN / SCHW / SWY /
Graham Jonathan P SVP, Gen. Counsel & Secy. 0.01%  (47756) AMGN / DHR /
COFFMAN VANCE D 0.01%  (43041) AMGN / DE / MMM /
Michael A Kelly Acting CFO 0.01%  (39177) AMGN /

Comments